While Apellis Pharmaceuticals Inc has underperformed by -2.28%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APLS fell by -22.22%, with highs and lows ranging from $35.57 to $16.10, whereas the simple moving average jumped by 13.31% in the last 200 days.
On November 06, 2025, Wolfe Research started tracking Apellis Pharmaceuticals Inc (NASDAQ: APLS) recommending Peer Perform. A report published by Wells Fargo on October 15, 2025, Initiated its previous ‘Overweight’ rating for APLS. Goldman also Downgraded APLS shares as ‘Sell’, setting a target price of $18 on the company’s shares in a report dated September 26, 2025. BofA Securities May 09, 2025d its ‘Buy’ rating to ‘Neutral’ for APLS, as published in its report on May 09, 2025. Cantor Fitzgerald’s report from April 29, 2025 suggests a price prediction of $44 for APLS shares, giving the stock a ‘Overweight’ rating. Goldman also rated the stock as ‘Neutral’.
Analysis of Apellis Pharmaceuticals Inc (APLS)
Further, the quarter-over-quarter increase in sales is 132.98%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Apellis Pharmaceuticals Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 14.10% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 2.65M can be a very valuable indicator of volatility for APLS stock. On a monthly basis, the volatility of the stock is set at 4.62%, whereas on a weekly basis, it is put at 5.00%, with a loss of -1.94% over the past seven days. Furthermore, long-term investors anticipate a median target price of $35.00, showing growth from the present price of $24.82, which can serve as yet another indication of whether APLS is worth investing in or should be passed over.
How Do You Analyze Apellis Pharmaceuticals Inc Shares?
The USA based company Apellis Pharmaceuticals Inc (APLS) is one of the biggest names in Biotechnology. When comparing Apellis Pharmaceuticals Inc shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 83.60, there is a growth in quarterly earnings of 458.67%.
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.99%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 99.29% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
